A Pragmatic Trial of Secondary Prophylaxis With Bezlotoxumab to Prevent C. Difficile Relapse Among Hospitalized Adults Receiving Antibiotics
Latest Information Update: 10 Nov 2022
At a glance
- Drugs Bezlotoxumab (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
Most Recent Events
- 13 Oct 2022 Status changed from recruiting to discontinued.
- 10 Jun 2022 Planned End Date changed from 15 Sep 2022 to 15 Sep 2023.
- 10 Jun 2022 Planned primary completion date changed from 15 May 2022 to 15 May 2023.